Everett Harris & Co. CA Reduces Holdings in Organon & Co. (NYSE:OGN)

Everett Harris & Co. CA decreased its position in Organon & Co. (NYSE:OGN) by 36.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,703 shares of the company’s stock after selling 29,885 shares during the period. Everett Harris & Co. CA’s holdings in Organon & Co. were worth $746,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in OGN. Fairfield Bush & CO. grew its stake in shares of Organon & Co. by 3.0% in the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock valued at $569,000 after buying an additional 481 shares during the period. Natixis Advisors L.P. grew its stake in shares of Organon & Co. by 52.5% in the 1st quarter. Natixis Advisors L.P. now owns 50,428 shares of the company’s stock valued at $1,761,000 after buying an additional 17,370 shares during the period. MetLife Investment Management LLC grew its stake in shares of Organon & Co. by 23.2% in the 1st quarter. MetLife Investment Management LLC now owns 68,987 shares of the company’s stock valued at $2,410,000 after buying an additional 12,969 shares during the period. Panagora Asset Management Inc. grew its stake in shares of Organon & Co. by 95.6% in the 1st quarter. Panagora Asset Management Inc. now owns 39,595 shares of the company’s stock valued at $1,383,000 after buying an additional 19,352 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Organon & Co. by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,926 shares of the company’s stock valued at $1,185,000 after buying an additional 2,101 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN traded up $0.35 during mid-day trading on Thursday, reaching $18.80. 2,254,203 shares of the company were exchanged, compared to its average volume of 2,913,939. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of 4.70, a P/E/G ratio of 0.86 and a beta of 0.81. The firm’s 50-day simple moving average is $17.47 and its 200 day simple moving average is $15.65. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.79.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. On average, research analysts forecast that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a dividend of $0.28 per share. The ex-dividend date was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.96%. Organon & Co.’s payout ratio is currently 28.00%.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver purchased 2,720 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now directly owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group increased their price target on shares of Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, February 20th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.